Moreover, cancer patients with high BCL9 expression had significantly worse overall survival than those with low BCL9 expression among the tumors exhibiting low immune infiltration, especially among those also displaying Wnt activity (Supplementary Fig. 2e). The gene discussed is BCL9; the disease is cancer.